MedTrace Logo

PolyArginine Treated vEiN grafTs (PATENT)

NCT00264706 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2016-09-08

No results posted yet for this study

Summary

The primary objectives of this trial are: 1) to evaluate the safety of NONA-L-ARGININE in ex vivo application to saphenous vein segments prior to grafting; and, 2) to obtain preliminary data on the biological effects of NONA-L-ARGININE, as compared to placebo, in the prevention of neointimal hyperplasia.

Conditions

  • Saphenous Vein Graft Disease

Interventions

DRUG

Nona-L-arginine

Sponsors & Collaborators

  • Lumen Therapeutics

    lead INDUSTRY

Principal Investigators

  • Stephanie Brister, M.D. · Toronto General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2008-04-30
Completion
2008-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00264706 on ClinicalTrials.gov